Aldagen, Inc.

Lyle A. Hohnke, Ph.D. has been appointed chief executive officer of Aldagen, Inc. Dr. Hohnke has more than 35 years of health care industry experience and has served on Aldagen’s board of directors since 2008. He succeeds Tom Amick.

“We appreciate the guidance Tom has given Aldagen over the years, and thank him for his many contributions that have brought the company to its current stage of development,” said Richard Kent, M.D., chairman of Aldagen. “Lyle’s involvement with the company as a board member, and his significant fundraising and operational experience make him a great addition to Aldagen’s executive management team.”

Dr. Hohnke was most recently a partner at Tullis Dickerson, a healthcare-focused venture capital fund. He has specific expertise in identifying and evaluating the commercial possibilities of new technologies, and in the technology transfer process. Prior to Tullis, Dr. Hohnke was a general partner of an Iowa-based venture capital fund, where he led a leveraged buyout of a division of Bayer A.G.